GemPharmatech Chairman Dr. Xiang Gao Presents Innovative Mouse Models at Leibniz-HKI in Germany

JENA, GERMANY On October 5, 2026, Dr. Xiang Gao, Chairman of GemPharmatech Co., Ltd., delivered a scientific seminar titled “From Models to Discovery: Advancing Translational Research Through Innovative Mouse Models” at the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (Leibniz-HKI) in Jena, Germany.

Held in the institute’s Koch and Pasteur seminar rooms, the event brought together researchers from Leibniz-HKI and the wider Beutenberg Campus as Gao introduced how mice are at the center of translational research; showing slides of GemPharmatech developing from a model resource into a full-service contract research organization (CRO). The talk continued with an in depth look at how different genetically engineered and humanized mouse models help connect basic research with preclinical evaluation and drug development.

GemPharmatech Meets European Animal Welfare and Quality Standards

“It was important to us to show how GemPharmatech is deeply aligned with European research standards in animal care and quality,” said Dr. Brandy Wilkinson, CEO of GemPharmatech North America and head of Business Development in Europe, who joined Gao during the seminar.

For European researchers, the quality of a model depends on the welfare standards and documentation behind it. GemPharmatech operates under an internationally recognized quality and animal welfare framework:

• AAALAC International accreditation, confirming high standards of animal care and use

• ISO 9001 Quality Management System certification, reflecting a commitment to consistent quality and customer focus

• OLAW Assurance, demonstrating compliance with U.S. Public Health Service Policy

• Active membership of the ICLAS Laboratory Animal Quality Network, linking GemPharmatech’s quality practices to a global network of research institutions

GemPharmatech’s animal care and use practices are guided by the 3Rs principles (Replacement, Reduction, and Refinement) and are aligned with key European regulations and guidelines, including:

• Directive 2010/63/EU on the protection of animals used for scientific purposes

• European Convention ETS 123 for the protection of vertebrate animals used for experimental and other scientific purposes

• FELASA guidelines, published by the Federation of European Laboratory Animal Science Associations

• ARRIVE 2.0 guidelines for reporting of in vivo experiments

This alignment spans the full animal care and use program, from environmental control and husbandry to veterinary care, training, and project review.

Supporting European Partners

GemPharmatech provides genetically engineered and humanized mouse models and integrated preclinical solutions to support research into disease mechanisms and therapeutic development. The company welcomes collaboration with European academic institutions, biotechnology companies, and pharmaceutical partners, and thanks Leibniz-HKI for hosting the seminar.

To discuss models and services for your research, contact our European team at sales@gempharmatech.com.

About GemPharmatech

GemPharmatech is a leading global contract research organization offering end-to-end integrated preclinical services, built on the world's largest library of genetically engineered mouse models and advanced in vivo platforms. With more than 30,000 strains of knockout, conditional knockout, humanized and immunodeficient mice, GemPharmatech enables researchers worldwide to accelerate therapeutic innovation across oncology, immunology, neurodegenerative diseases and beyond. The company also provides custom model generation and microbiome research services, along with custom breeding and vivarium rental services.

Read the original news from Leibniz-HKI: https://www.leibniz-hki.de/en/mbd-newsdetails/from-models-to-discovery-dr-xiang-gao-discusses-innovative-mouse-models-for-translational-research.html